Organogenesis Holdings Inc. (ORGO) shares rose 6.48 percent, up $0.145 to $2.385 on Tuesday, after the company announced positive results from a randomized controlled trial evaluating PuraPly AM in non-healing diabetic foot ulcers.
The stock is currently trading at $2.385, above its previous close of $2.24, after opening at $2.49 on the Nasdaq. Shares traded in a range of $2.37 to $2.63 during the session, with volume surging to 12.63 million shares, far above the average daily volume of 669,888.
Organogenesis' 52-week range is $2.21 to $7.077. The company said the 170-patient multi-center trial achieved its primary endpoint, showing statistically significant wound closure at 12 weeks versus standard of care alone, with a p-value below 0.0477. Management said the results support broader clinical evidence for PuraPly AM and may strengthen future reimbursement and coverage discussions in diabetic wound care.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.